Higher levels of plasma phosphatidylcholine (17:0_18:1) raise the risk of developing Parkinson’s disease

Higher levels of plasma phosphatidylcholine (17:0_18:1) raise the risk of developing Parkinson’s disease

Abstract Emerging evidence suggests that dysregulation of lipid metabolism and chronic inflammation in the central nervous system (CNS) contribute to the risk of Parkinson’s disease (PD). However, the causal relationship between plasma lipid metabolism and PD, particularly through immune modulation,...

Full description

Saved in:
Bibliographic Details
Main Authors: Daoqing Su, Yajun Jing, Jinye Su, Honglin Zhu, Yiming Chen, Qiu He, Dengliang Wang, Dezhi Kang, Yuanxiang Lin
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Lipid metabolism
Parkinson’s disease
Circulating inflammatory proteins
Circulating immune cells
Mendelian randomization analysis
Online Access:https://doi.org/10.1038/s41598-025-12054-y
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Emerging evidence suggests that dysregulation of lipid metabolism and chronic inflammation in the central nervous system (CNS) contribute to the risk of Parkinson’s disease (PD). However, the causal relationship between plasma lipid metabolism and PD, particularly through immune modulation, remains unclear. In this study, we used Mendelian randomization (MR) to investigate the causal association between plasma lipidome and PD risk, utilizing GWAS summary statistics for PD, circulating immune cells, inflammatory proteins, and plasma lipidome. We found that higher plasma phosphatidylcholine (17:0_18:1) levels were causally associated with an increased risk of PD, with a 1 standard deviation genetically instrumented higher level corresponding to a 30% increased risk (95% CI 1.05–1.61, p = 0.014). Multivariate Mendelian randomization (MVMR) analysis confirmed this association after adjusting for triacylglycerol levels. Mediation analysis revealed that the causal link between plasma phosphatidylcholine and PD was mediated by circulating immune cells (specifically CD45 on CD14+ monocytes and CD45 on HLA-DR+ T cells) rather than by circulating inflammatory proteins. These findings highlight a novel pathway linking lipid metabolism, immune modulation, and PD risk.
ISSN:2045-2322

Similar Items